Research programme: quinolone antibacterials - Procter & Gamble

Drug Profile

Research programme: quinolone antibacterials - Procter & Gamble

Alternative Names: (3S)-Amino-(4R)-ethylpiperidinyl quinolones research programme - Procter & Gamble; 5,6-Bridged dioxinoquinolones research programme - Procter & Gamble; Non-fluorinated quinolones research programme - Procter & Gamble; PGE 836779; Quinolone antibacterials research programme - Procter & Gamble

Latest Information Update: 01 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Class Quinolones
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 06 Jan 2005 TaiGen Biotechnology entered a strategic alliance with Procter & Gamble for further development and commercialisation of an unspecified, non-fluorinated quinolone invented by Procter & Gamble. TaiGen has development and commercialisation rights in China, Taiwan, Korea and the ASEAN countries
  • 07 Jan 2004 A preclinical study has been added to the Bacterial Infections antimicrobial activity section
  • 05 Sep 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top